Testing a focused radiation treatment for cancer that has spread to the brain
Original title: Phase I Study of Fractionated Stereotactic Radiation Therapy
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early study to check safety and dosing in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing how safe a focused form of radiation is for people with brain tumors that started as cancer somewhere else.
Who this trial is for. This trial is for people who have brain metastases, which is cancer that spread to the brain from another part of the body. It is testing a treatment called fractionated stereotactic radiation therapy, which aims radiation at the tumor and gives it over more than one session.
Where it stands. This trial has not reported results. The team is looking at whether the treatment can be done safely, and at how much radiation people can be given without too much harm. The answer is not in yet. The study team says the results will be used to plan later studies that look at how well different dosing schedules work.
What this means, and what it doesn't
What it could mean: There has not been this kind of planned study of this treatment for brain metastases before. So this trial is meant to answer a basic question about safety and dosing. If this sounds like your situation, you can ask your care team whether a trial like this is worth looking into for you.
What it doesn't mean: This does not mean the treatment is proven. A trial is a test, not care your own doctor can give you yet. Joining a trial does not mean you will be helped, and it is not a promise of a cure. Whether anyone can join is decided by the trial team, not by us.
Source: ClinicalTrials.gov, August 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.